作者
May E. Montasser,Cristopher V. Van Hout,Lawrence Miloscio,Alicia Howard,Avraham Rosenberg,Myrasol Callaway,Biao Shen,Ning Li,Adam E. Locke,Niek Verweij,Tanima De,Manuel A. R. Ferreira,Luca A. Lotta,Aris Baras,Thomas J. Daly,Suzanne A. Hartford,Wei Lin,Yuan Mao,Bin Ye,Derek W. R. White,Guochun Gong,James A. Perry,Kathleen A. Ryan,Qing Fang,Gannie Tzoneva,Evangelos Pefanis,Charleen Hunt,Yajun Tang,Lynn Lee,Carole Sztalryd-Woodle,Braxton D. Mitchell,Matthew Healy,Elizabeth A. Streeten,Simeon I. Taylor,Jeffrey R. O’Connell,Aris N. Economides,Giusy Della Gatta,Alan R. Shuldiner
摘要
Rare variants and blood LDL cholesterol A current goal in genomics is to identify genetic variation associated with actionable traits of clinical concern. Through exome sequencing of an Old Order Amish population, Montasser et al . identified a genetic variant that results in an amino acid change in the beta-1,4-galactosyltransferase 1 protein and is correlated with lower levels of cardiovascular disease. Investigation of the mutant protein showed that it affects genes associated with low-density lipoprotein cholesterol (LDL-C), and mice engineered to express the mutant protein exhibited a 38% decrease in blood LDL-C levels. This study suggests that such genomic sequencing and analysis can link genotype to phenotype and identify potentially clinically actionable pathways to treat disease. —LMZ